HILLEVAX INC (HLVX) Stock Overview
USA - NASDAQ:HLVX - US43157M1027 - Common Stock
HLVX Key Statistics, Chart & Performance
The current stock price of HLVX is 2.09 USD. In the past month the price increased by 1.46%. In the past year, price increased by 16.11%.
HLVX Latest News, Press Relases and Analysis
HLVX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.93B | ||
| ARGX | ARGENX SE - ADR | 89.07 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.96 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 9.34 | 21.93B |
Related stock screener links
About HLVX
Company Profile
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Company Info
HILLEVAX INC
321 Harrison Ave, Suite 500
Boston MASSACHUSETTS US
Employees: 14
Phone: 16172135054
HILLEVAX INC / HLVX FAQ
Can you describe the business of HILLEVAX INC?
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
What is the current price of HLVX stock?
The current stock price of HLVX is 2.09 USD. The price decreased by -0.48% in the last trading session.
Does HLVX stock pay dividends?
HLVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of HLVX stock?
HLVX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does HILLEVAX INC have?
HILLEVAX INC (HLVX) currently has 14 employees.
What is the market capitalization of HLVX stock?
HILLEVAX INC (HLVX) has a market capitalization of 104.79M USD. This makes HLVX a Micro Cap stock.
HLVX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to HLVX. When comparing the yearly performance of all stocks, HLVX is one of the better performing stocks in the market, outperforming 74.76% of all stocks.
HLVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to HLVX. No worries on liquidiy or solvency for HLVX as it has an excellent financial health rating, but there are worries on the profitability.
HLVX Financial Highlights
Over the last trailing twelve months HLVX reported a non-GAAP Earnings per Share(EPS) of -1.43. The EPS increased by 57.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.65% | ||
| ROE | -48.1% | ||
| Debt/Equity | 0 |
HLVX Forecast & Estimates
6 analysts have analysed HLVX and the average price target is 2.04 USD. This implies a price decrease of -2.39% is expected in the next year compared to the current price of 2.09.